- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00325338
Follow-up Investigation of Efficacy of Ragweed MATAMPL,and Placebo in Patients With Ragweed-induced Seasonal Allergic Rhinitis
June 16, 2010 updated by: Allergy Therapeutics
Follow-up Study to Evaluate the Sustained Clinical Efficacy of Ragweed MATA MPL (Allergy Therapeutics®) in Patients With Ragweed-induced Seasonal Allergic Rhinitis Upon Re-exposure to Ragweed Pollen in an Environmental Exposure Chamber (EEC) Model, Approximately One Year After Pre-seasonal Treatment in 2005
Ragweed MATAMPL has been developed to provide pre-seasonal specific immunotherapy for patients with hypersensitivity to ragweed pollen (hay fever).
This novel formulation is designed to provide a vaccine that will be efficacious with only four escalating dose injections administered before the start of the pollen season.
In this Follow-up Study the Efficacy will be assessed by exposing allergic subjects to Ragweed pollen in an environmental exposure chamber EEC.
Patient symptomatic response to pollen and patient quality of life in the EEC will be determined.
Patients who previously completed two EEC portions of study Ragweed MATAMPL 204 and who had been treated with either Ragweed MATA MPL or Placebo before the 2005 ragweed season will be enrolled.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment
100
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Mississauga, Ontario, Canada, L4W 1N2
- Allied Research International Inc.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients must have completed both EEC periods of study P2DP5001; have had received either placebo or the top dose if they had been treated with Ragweed MATA MPL; and have had no major changes in medical history or health status since completing the study.
- Patients must be willing and able to give written informed consent and provide this consent prior to initiation of any study procedures, including initiation of washout of any concomitant medications.
- Patients must be willing and able to attend all study visits.
- Patients must observe the drug washout times listed in Table 3.2.3 prior to Screening (Visit 1). The use of other concomitant medications will be permitted if they are not expected to interfere with the ability of the patient to participate in the study and provided that they have been on a stable regimen (i.e. the same dose and schedule of administration) for eight weeks prior to screening).
Women of childbearing potential must be using one of the following acceptable birth control methods:
- Intrauterine device (IUD) in place for at least three months;
- Barrier method (condom or diaphragm) with spermicide;
- Stable hormonal contraceptive for at least three months prior to study and through study completion;
- Abstinence;
- Not-heterosexual lifestyle.
- Patients must be able to follow instructions
Exclusion Criteria:
- Symptomatic for allergic rhinitis or allergic conjunctivitis from allergy to grass or trees at Visit 1.
- Symptomatic for significant perennial rhinitis at Visit 1, as judged by the Investigator.
- Concurrent disease that might complicate or interfere with investigation or evaluation of the study medication such as:
- Chronic use of antihistamines and other concomitant medications (e.g. tricyclic antidepressants) that would affect assessment of the effectiveness of study drug.
- Any systemic disorder that could interfere with the evaluation of the study medication.
- Upper or lower respiratory tract infection requiring antibiotics with 14 days of Visit 2.
- Diagnosis of sinusitis within 30 days of Visit 2.
- Any ocular disorder (other than allergic conjunctivitis) including presumed infectious ocular disease (bacterial, fungal, viral, etc.), which could interfere with the evaluation of the study drug.
- Hypersensitivity to the study drug excipients.
- Patients with active or quiescent tuberculous infection of the respiratory tract, untreated local or systemic fungal infection or bacterial or systemic viral infections or parasitic or ocular herpes simplex.
- Patients who have experienced nasal ulcers, nasal surgery or nasal trauma within 90 days of enrollment into this study.
- Clinical history of anaphylaxis or idiopathic anaphylaxis.
- Patients with contraindications for allergy vaccines.
- Patients with a clinical history of immunodeficiency, including those who are on immunosuppressant therapy.
- Patients in whom tyrosine metabolism is disturbed, especially in the case of tyrosinemia and alkaptonuria.
- Patients with contraindication to adrenaline.
- Subjects who are taking β-blockers for any indication including eye drops.
- Current diagnosis of chickenpox or measles.
- Clinical history of drug or alcohol abuse, at the Investigator's discretion, that would interfere with the patient's participation in the study.
- Clinical history of severe or uncontrolled cardiovascular, hepatic, renal and/or other diseases/illness that could be expected to interfere with the study.
- Clinical history, or evidence, of nasolacrimal drainage system malfunction.
- Study site staff or immediate relatives of study site staff or other individuals who would have access to the clinical study protocol.
- Patient who have participated in any other investigational study within 30 days of Visit 1 or concomitant with this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
to assess whether the efficacy of RagweedMATAMPL is maintained approximately one year later during the first EEC period of 2006
|
Secondary Outcome Measures
Outcome Measure |
---|
Determine whether the lack of efficacy observed for Ragweed MATA MPL in 2005 will manifest itself approximately one year later
|
Determine whether the immunoglobulin levels measured after treatment with Ragweed MATA MPL in 2005 have changed approximately one year later.
|
Determine whether the responses to the RQLQ-EEC measured after treatment with Ragweed MATA MPL in 2005 have changed approximately one year later.
|
Determine whether a second treatment in 2006 will modify the efficacy observed in 2005 and maintained approximately one year later in patients who had been treated with Ragweed MATA MPL.
|
Determine whether a second treatment in 2006 will modify the efficacy observed in 2005 and partially or completely lost approximately one year later in patients who had been treated with Ragweed MATA MPL
|
Determine whether a second treatment in 2006 will confer or improve the efficacy in patients who moderately responded or did not respond to Ragweed MATA MPL in 2005
|
Determine whether a second treatment in 2006 will modify the extent of the immunoglobulin response observed in 2005 in patients who had been treated with Ragweed MATA MPL
|
Determine whether a second treatment in 2006 will modify the responses to the RQLQ-EEC recorded before and after treatment in 2005
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2006
Study Completion
July 1, 2006
Study Registration Dates
First Submitted
May 11, 2006
First Submitted That Met QC Criteria
May 11, 2006
First Posted (Estimate)
May 12, 2006
Study Record Updates
Last Update Posted (Estimate)
June 17, 2010
Last Update Submitted That Met QC Criteria
June 16, 2010
Last Verified
June 1, 2010
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RagweedMATAMPL205
- P2DP05007
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type I Hypersensitivity
-
Allergy TherapeuticsCompleted
-
Allergy TherapeuticsCompletedType I HypersensitivityCanada
-
Allergy TherapeuticsCompletedType I HypersensitivityUnited States, Canada, United Kingdom, Austria
-
Allergy TherapeuticsCompletedType I HypersensitivityUnited States
-
Allergy TherapeuticsCompletedType I HypersensitivityUnited States
-
Allergy TherapeuticsCompletedType I HypersensitivityGermany
-
Allergy TherapeuticsCompletedType I HypersensitivityCanada
-
Allergy TherapeuticsCompleted
-
Allergy TherapeuticsCompletedType I HypersensitivityUnited States
-
Allergy TherapeuticsWithdrawnType I HypersensitivityCanada
Clinical Trials on Ragweed MATAMPL
-
Allergy TherapeuticsCompletedType I HypersensitivityCanada
-
The University of Texas Medical Branch, GalvestonCompleted
-
Circassia LimitedCetero Research, San Antonio; Adiga Life Sciences, Inc.Completed
-
Circassia LimitedCetero Research, San Antonio; Adiga Life Sciences, Inc.Completed
-
Allergy TherapeuticsCompleted
-
Circassia LimitedAdiga Life Sciences, Inc.Completed
-
Circassia LimitedAdiga Life Sciences, Inc.CompletedSeasonal Allergic RhinitisCanada
-
Circassia LimitedAdiga Life Sciences, Inc.CompletedAsthma | Seasonal Allergic RhinitisCanada
-
Circassia LimitedCetero Research, San Antonio; Adiga Life Sciences, Inc.Completed